Sürdürülebilir Kalkınma Amaçları
Yayınlar
- MakaleYalnız künye2024Investigation of The Relationship Between COVID-19 Severity and Serum Adropin Levels
Tor, Ibrahim Hakki; Aydın, Pelin; Uzunçakmak, Sevgi Karabulut; Halici, Hamza; Özçelik, Cihad
Objective: COVID-19 is a multisystemic disease with high mortality and morbidity. It is very important to understand the pathogenesis of the disease and to develop pharmacological treatment methods. The aim of this study was to measure serum adropin levels in COVID-19 patients in the ward and intensive care unit and to investigate whether this value can be a prognostic factor or a pharmacological treatment target. Methods: 116 volunteer participants were included in the study. Participants were grouped as the control group consisting of patients without any disease, patients diagnosed with COVID-19 and hospitalised in the ward, patients diagnosed with COVID-19 and hospitalised in Level 2 intensive care and patients diagnosed with COVID- 19 and hospitalised in Level 3 intensive care. Venous blood was taken from the patients. Serum adropin levels were measured according to the manufacturer's instructions. ROC analysis was also performed. Results: According to serum adropin measurements, serum adropin levels of patients with COVID-19 who were hospitalised in the ward decreased compared to the control group. In Level 2 intensive care and Level 3 intensive care patients, serum adropin levels decreased compared to patients in the ward. According to Roc analysis, 333.1 ng/L adropin had a specificity of 0.8167 (95%, 0.6956-0.9048) and a sensitivity of 0.6522 (95%, 0.4273-0.8362). Conclusion: COVID-19 is a disease with high mortality and morbidity affecting all systems. With this study, we think that serum adropin levels may be a prognostic factor or a new pharmacological treatment target and may shed light on new studies.
- MakaleYalnız künye2022Scopus SJRQ1Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-κB-NLRP3 Inflammasome Signaling Pathway
Aydin, Pelin; Magden, Zeynep Berna Aksakalli; Uzuncakmak, Sevgi Karabulut; Halici, Hamza; Akgun, Nurullah; Mendil, Ali Sefa; Mokhtare, Behzad; Cadirci, Elif
Aim: We demonstrate the effect of PDE5 inhibitors in cases of acute lung injury via the relationship between cGMP/NO and the TLR4-NF-κB-NLRP3 pathway. Materials and Methods: This study was performed with 30 male Wistar albino rats. Lipopolysaccharide (LPS) was administered intratracheally to the rats and acute lung injury (ALI) was induced. Twelve hours after LPS administration, avanafil, prepared at suitable doses according to the body weights of the animals, was administered by oral gavage. Lung tissue samples of all groups were examined histopathologically and by immunochemical staining (IL-1β, iNOS, TLR4, and NF-κB). The iNOS, NLRP3, and IL-1B mRNA expression levels in the lung tissues were measured by RT-PCR. The left upper lobes of the rat lungs were dried at 70 °C for 48 h and lung water content was calculated. Result: Statistically significant increases in iNOS, NLRP3, and IL-1β mRNA expressions were observed in the rats with ALI compared to the healthy controls (p < 0.0001). Those increased expressions were reduced at both doses of avanafil (p < 0.0001). This reduction was found to be greater at 20 mg/kg (p < 0.0001). IL-1β, iNOS, TLR4, and NF-κB immunopositivity was moderate/severe in the ALI group and mild in the group with ALI + avanafil at 20 mg/kg (p < 0.05). When the wet/dry lung ratios were calculated, a statistically significant increase was seen in the ALI group compared to the healthy rats (p < 0.05). That increase was decreased with both avanafil doses (p < 0.05). Conclusion: We suggest that avanafil may prevent the progression of ALI and be effective in its treatment. We hope that this study will be supported by future clinical studies to yield a new indication for avanafil.
AtıfScopus18WoS21OpenAlex17
İncele
